NCT07552532

Brief Summary

This multicenter retrospective study is designed to develop and validate a CT-based multimodal risk stratification approach for postoperative local recurrence after curative-intent resection of non-small cell lung cancer (NSCLC). The approach integrates clinicopathologic variables, intratumoral and peritumoral radiomics, tumor-based 2.5D deep learning features, whole-lung deep learning features, and operative text features to capture complementary information related to tumor phenotype, pulmonary background, and surgical findings. Predictive performance and clinical utility will be evaluated in internal and external validation cohorts using the concordance index, time-dependent area under the receiver operating characteristic curve, decision curve analysis, and risk reclassification analyses. The objective of this study is to assess whether multimodal CT-based risk stratification may improve postoperative risk assessment and support individualized surveillance and management strategies.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
1mo left

Started Jan 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress98%
Jan 2023Jun 2026

Study Start

First participant enrolled

January 1, 2023

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2026

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

April 14, 2026

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 27, 2026

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2026

Expected
Last Updated

April 27, 2026

Status Verified

April 1, 2026

Enrollment Period

3.1 years

First QC Date

April 14, 2026

Last Update Submit

April 20, 2026

Conditions

Keywords

local recurrencerisk stratificationradiomicsdeep learning

Outcome Measures

Primary Outcomes (1)

  • Postoperative local recurrence

    From the date of surgery to first documented local recurrence, up to 3 years

Study Arms (2)

local recurrence after surgery

The primary endpoint was postoperative local recurrence, defined as recurrence within the ipsilateral hemithorax, including the bronchial stump or parenchymal margin, ipsilateral hilar or mediastinal lymph nodes, and pleural or chest wall seeding. Local recurrence was primarily determined by serial imaging assessment, with PET/CT and pathology used when necessary. To distinguish recurrence from a new primary lung cancer, lesion location, imaging features, histology, and timing were considered comprehensively.

non-local recurrence

stable or distant metastasis or death during follow-up

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with pathologically confirmed non-small cell lung cancer (NSCLC) who underwent curative-intent surgical resection and had preoperative contrast-enhanced chest CT available were retrospectively identified from participating centers. Eligible patients had complete clinicopathological, imaging, and follow-up data for assessment of postoperative local recurrence.

You may qualify if:

  • Pathologically confirmed non-small cell lung cancer (NSCLC)
  • Preoperative contrast-enhanced chest CT performed within 2 weeks before surgery
  • Underwent routine postoperative follow-up

You may not qualify if:

  • Small cell lung cancer or metastatic tumors
  • Incomplete resection (R1/R2)
  • No preoperative contrast-enhanced CT performed within 2 weeks before surgery
  • History of other malignancies
  • Inadequate follow-up or follow-up duration of 3 months or less

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jinling Hospital

Nanjing, Jiangsu, 210002, China

Location

MeSH Terms

Conditions

Lung NeoplasmsCarcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesCarcinoma, BronchogenicBronchial Neoplasms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 14, 2026

First Posted

April 27, 2026

Study Start

January 1, 2023

Primary Completion

February 1, 2026

Study Completion (Estimated)

June 1, 2026

Last Updated

April 27, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will share
Shared Documents
STUDY PROTOCOL

Locations